Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biohaven Ltd (BHVN)

Biohaven Ltd (BHVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Canada Jobs in Focus Next Week

Monday U.S. Featured Earnings Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (Q1) EPS of $3.66, ...

ESI.TO : 2.22 (-1.33%)
FTT.TO : 39.84 (-1.34%)
SU.TO : 51.59 (-0.35%)
VRTX : 478.04 (+0.65%)
MCHP : 89.54 (+0.40%)
PLTR : 24.35 (+0.79%)
DIS : 102.29 (+0.30%)
ANET : 332.58 (+1.02%)
TM : 206.10 (+3.58%)
UBER : 71.83 (+1.83%)
ABNB : 150.60 (+1.49%)
HMC : 32.29 (+1.48%)
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®

- Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscular disorders and metabolic diseases including...

BHVN : 34.75 (+0.03%)
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 34.75 (+0.03%)
Markets Today: Stocks Decline as Bond Yields Soar

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.61%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.76%. Stock index futures this morning are moderately lower, weighed...

ESU24 : 5,520.50 (+0.06%)
NQU24 : 19,840.75 (+0.46%)
MCK : 610.50 (+0.44%)
BHVN : 34.75 (+0.03%)
ABNB : 150.60 (+1.49%)
KLG : 17.26 (+0.12%)
HPQ : 36.33 (+0.08%)
DOW : 53.79 (-1.52%)
LYB : 96.37 (-1.18%)
FVRR : 22.38 (+0.95%)
DY : 166.62 (+0.10%)
PNT : 12.50 (+0.16%)
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 34.75 (+0.03%)
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

BHVN : 34.75 (+0.03%)
Why Biohaven Stock Is Skyrocketing Today

Promising clinical trial data led investors to bid the stock up, adding to its solid year-to-date gain.

BHVN : 34.75 (+0.03%)
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and...

BHVN : 34.75 (+0.03%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are...

BHVN : 34.75 (+0.03%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are...

BHVN : 34.75 (+0.03%)

Barchart Exclusives

Insider Selling in Nvidia Stock Hits an All-Time High, is This a Red Flag?
CEO Jensen Huang is among the insiders that have been heavy sellers of AI darling Nvidia lately. Should you follow suit and dump the stock, or ignore the executive selling activity? Here's a closer look. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar